Provided by Tiger Trade Technology Pte. Ltd.

Arbutus Biopharma

3.84
+0.17004.63%
Post-market: 3.990.1500+3.91%19:54 EST
Volume:2.56M
Turnover:9.75M
Market Cap:738.52M
PE:-17.10
High:3.90
Open:3.84
Low:3.67
Close:3.67
52wk High:5.10
52wk Low:2.71
Shares:192.32M
Float Shares:126.05M
Volume Ratio:1.05
T/O Rate:2.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2246
EPS(LYR):-0.3800
ROE:-45.88%
ROA:-16.46%
PB:9.54
PE(LYR):-10.11

Loading ...

Arbutus Biopharma Secures Mixed Ruling in Moderna Patent Case

TIPRANKS
·
Yesterday

Arbutus Biopharma Corp - U.S. Court Issues Memorandum in Arbutus VS. Moderna Case - SEC Filing

THOMSON REUTERS
·
Yesterday

Arbutus faces higher bar to argue infringement by Moderna, says Jefferies

TIPRANKS
·
Feb 03

Moderna reverses lower after court issues memo in patent fight with Arbutus

TIPRANKS
·
Feb 03

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:38 PM

Reuters
·
Feb 03

Nasdaq Net Change Percentage Gainers & Losers

Dow Jones
·
Jan 21

European Patent Office ruling ‘clear win’ for Moderna, says Citi

TIPRANKS
·
Jan 20

Arbutus says European patent revoked by European Patent Office

TIPRANKS
·
Jan 20

Sector Update: Health Care Stocks Retreat Late Afternoon

MT Newswires Live
·
Jan 17

Top Midday Decliners

MT Newswires Live
·
Jan 17

Arbutus Biopharma Down Over 14%, on Pace for Largest Percent Decrease Since July 2020 -- Data Talk

Dow Jones
·
Jan 17

BRIEF-Arbutus Biopharma Corp - EPO Revokes Arbutus Biopharma's European Patent EP 2279254 - SEC Filing

Reuters
·
Jan 16

Arbutus Biopharma Corp: Co Disagrees With Outcome, Plans to File Petition for Review by Enlarged Board of Appeal of Epo

THOMSON REUTERS
·
Jan 16

Arbutus Biopharma Corp - Epo Revokes Arbutus Biopharma's European Patent Ep 2279254 - SEC Filing

THOMSON REUTERS
·
Jan 16

European Patent Office Revokes Arbutus Biopharma Patent Amid Ongoing Litigation

Reuters
·
Jan 16

Trevi Therapeutics Names David Hastings CFO

MT Newswires Live
·
Dec 04, 2025

Arbutus Biopharma Q3 Revenue USD 500 Thousand

Reuters
·
Nov 20, 2025

Arbutus Biopharma Is Maintained at Buy by Chardan Capital

Dow Jones
·
Nov 15, 2025

Arbutus Biopharma Q3 revenue and net loss miss analyst estimates

Reuters
·
Nov 13, 2025

Earnings Flash (ABUS) Arbutus Biopharma Posts Q3 Loss $0.04 a Share, vs. FactSet Est of $0.03 Loss

MT Newswires Live
·
Nov 13, 2025